26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
13 October 2022 - BasileaBasilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity…read more >>
05 October 2022 - DEINOVE to present data on DNV3837 at the ESCMID/ASM conference in DublinDNV3837 – a prodrug of the DNV3681 molecule (also known as MCB3681) – is a narrow-spectrum, hybrid oxazolidinone-quinolone synthetic antibiotic…read more >>
13 September 2022 - ABAC therapeuticsABAC Therapeutics: Scientists from Spain and India Lead an International Project to Develop New Antibiotics Against Gram-Negative BacteriaABAC Therapeutics, together with the artificial intelligence (AI) company, Peptris, and the Foundation for Neglected Disease Research (FNDR), with scientific…read more >>
07 September 2022 - Debiopharm InternationalOne Drug for One Bug: Debiopharm to discuss the potential of pathogen-specific antibiotics at the 2022 World AMR CongressNow is the time to encourage the development of new antibiotic classes by establishing new business models that will assure…read more >>
07 September 2022 - Destiny Pharma plcDestiny Pharma announces positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plansDestiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening…read more >>
31 August 2022 - Omnix MedicalOmnix Medical received NIH grant for the development of its novel antimicrobial peptide OMN6Omnix Medical is developing a promising pipeline of novel anti-infective agents based on a new approach of fighting infectious diseases,…read more >>
17 March 2025BIO-Europe Spring® 2025 – 19th Annual International Partnering ConferenceBIO-Europe Spring will bring together over 3,700 leading executives from around the world. Specifically, we will host more than 20,000…read more >>
25 February 20259th AMR ConferenceSave the date! The 9th AMR Conference will be organized as a face-to-face event on 25-26 February 2025, in Basel.…read more >>
03 December 2024REVIVE Webinar: Implementation research for the appropriate use of, and access to, antimicrobialsThis webinar will explore how implementation research has successfully led to the updating of guidelines for other drugs and discuss…read more >>
04 November 2024BIO-Europe ® 2024 – 30th Annual International Partnering ConferenceOver the last 30 years, BIO-Europe, has become Europe’s flagship partnering event. Its international reach makes it a one-of-a-kind offering,…read more >>
19 September 2024REVIVE Webinar: An introduction to antibiotic research and development (R&D)Itroduction to the stages from discovery to the phases of clinical trials and pharmaceutical development - A must-watch for clinicians…read more >>
22 August 2024REVIVE Webinar: Exploring non-traditional antimicrobials: Insights from three casesFind out the latest in the development of non-traditional antimicrobials from Jennifer Schneider at Centauri Therapeutics, Rida Mourtada at Lytica…read more >>
23 July 2024REVIVE Webinar: The value of surveillance data in defining the medical need for new antimicrobialsIn this webinar, the speakers will show the value of susceptibility surveillance data in defining the need for new antibacterials,…read more >>
27 June 2024REVIVE Webinar: Progressing an antibacterial drug discovery project – an SME perspectiveAlisa Serio from Paratek Pharma and Victoria Savage from INFEX Therapeutics will focus on the particular challenges, progression criteria and…read more >>
23 April 2024REVIVE Webinar: Efflux inhibitors: A strategy to tackle multidrug resistanceThe next REVIVE webinar will feature an overview of bacterial efflux and how molecules designed to inhibit this can be…read more >>
